About Us

Who We Are

The Johns Hopkins University Baltimore-Washington-India Clinical Trials Unit (BWI CTU) is a collaboration and integration of 3 separate Clinical Research Sites (CRS’s):
 

The BWI CTU supports clinical studies offered by 4 NIAID Clinical Research Networks

  1. AIDS Clinical Trials Group (ACTG)
  2. HIV Prevention Trials Network (HPTN)
  3. International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
  4. Antibiotic Resistance Leadership Group (ALRG).

The BWI CTU works with patients from two diverse, urban U.S. communities with high burdens of and high risks for HIV and Hepatitis C (Baltimore and Washington, DC), as well as one of the largest HIV/infectious diseases clinical care and clinical research units on the Indian subcontinent.

The BWI CTU includes a highly experienced international leadership that is also uniquely positioned to make significant and strategic scientific contributions. 
 

Three Specific Aims

  1. Science. The BWI CTU’s innovative Scientific Coordinating Committees bring together expertise in our strongest fields: Tuberculosis, Hepatitis, HIV Cure, HIV Prevention, Clinical Pharmacology, Pediatric & Adolescent Research, Inflammation & End-Organ Complications, Antibiotic Resistance, and Training & Mentorship.

    The Committees are highly creative in developing new study proposals, identifying and prioritizing studies for site implementation, and encouraging young and international investigators to contribute to novel scientific concepts valued by the networks we support.

  2. Populations. Our three CRS sites work with very important and often under-represented populations.

    1. Impoverished urban African-Americans and other communities of color, those with a history of intravenous drug use and substance abuse in Baltimore and Washington
    2. Vulnerable sexually active young urban MSM and women in Baltimore and Washington
    3. Pregnant women, adolescents and adults in urban India.


    Because all three sites provide top-quality clinical care and clinical research at the same facility, we can efficiently identify potential research participants and rapidly enroll them into high priority research using our integrated clinical care and clinical research teams.

  3. Management. Our efficient and highly integrated administrative structure facilitates high quality clinical research while taking advantage of shared resources, investigator expertise and synergies among sites.

Clinical Trials

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More